Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for JAMES BLOOM
51.29
+1.68 (3.39%)
Oct 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 48.15 - 51.44
52 week 34.28 - 54.25
Open 49.40
Vol / Avg. 1.08M/1.02M
Mkt cap 7.23B
P/E     -
Div/yield     -
EPS -0.07
Shares 145.83M
Beta 1.18
Inst. own 97%
Dec 2, 2014
Alkermes Plc at NASDAQ OMX Investor Program Add to calendar
Nov 11, 2014
Alkermes Plc at Credit Suisse Healthcare Conference - 1:00PM EST - Add to calendar
Oct 29, 2014
Q3 2014 Alkermes Plc Earnings Release
Oct 29, 2014
Q3 2014 Alkermes Plc Earnings Call - Webcast
Sep 8, 2014
Alkermes Plc at Morgan Stanley Healthcare Conference - Webcast
Sep 3, 2014
Alkermes Plc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 2.43% -
Operating margin -14.88% -
EBITD margin - -
Return on average assets 0.81% -
Return on average equity 1.11% -
Employees 1,250 -
CDP Score - -

Address

Connaught House 1 Burlington Road, Dublin 4
DUBLIN,
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane Cooke President
Age: 51
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 55
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President
Age: 38
Bio & Compensation  - Reuters
James L. Botkin Senior Vice President - Operations
Age: 64
Bio & Compensation  - Reuters